This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Read these articles for the latest news on Gilead’s international production, distribution, and pricing of its new hepatitis C drug, SOVALDI:
-
Article in Bloomberg Mag (Gilead Close to Sending $84,000 Drug to Poor Countries) explaining how/why pricing differs throughout the world: http://www.bloomberg.com/news/2014-09-04/gilead-close-to-sending-84-000-drug-to-poor-countries.html
-
Great quote at the end of this Businessweek article (Britain Has No Problem Paying for Expensive Hepatitis C Drugs) about how UK’s public medical services plan is paying to treat UK patients with SOVALDI: “Americans sometimes accuse Britain’s single-payer system of rationing of health care. In the case of a cure for hepatitis C, it seems the single-payer model is doing the opposite.” http://www.businessweek.com/articles/2014-08-18/sovaldi-why-the-u-dot-k-dot-will-pay-for-the-84-000-hepatitis-c-drug